Keyphrases
Cholangiocarcinoma
100%
Present Challenges
100%
Molecular Therapeutic Targets
100%
Genetic Modification
50%
Driver Alterations
50%
Future Therapeutics
25%
Treatment Response
25%
Patient's Will
25%
Incidence Rate
25%
Mortality Rate
25%
Combination Therapy
25%
Immune System
25%
Poor Prognosis
25%
Therapeutic Challenges
25%
Advanced Disease
25%
Clinical Benefit
25%
Patient-centered
25%
Oncogene
25%
Tumor Suppressor
25%
Non-genetic
25%
Microenvironment
25%
Drug Target
25%
Tumor Survival
25%
Targeted Agents
25%
Prognosis Treatment
25%
Limited Treatment Options
25%
Fibroblast Growth Factor Receptor 2 (FGFR2)
25%
FDA-approved Drugs
25%
Treatment Resistance
25%
Genetic Identification
25%
Clinical Trial Results
25%
Multikinase Inhibitor
25%
Non-oncogene Addiction
25%
Precision Oncology
25%
Basket Trial
25%
Druggability
25%
Future Solutions
25%
Inevitability
25%
Disease Resistance Mechanism
25%
Isocitrate Dehydrogenase 1 mutation
25%
Medicine and Dentistry
Cholangiocarcinoma
100%
Disease
50%
Mortality Rate
25%
Neoplasm
25%
Biological Marker
25%
Combination Therapy
25%
Recurrent Disease
25%
Treatment Response
25%
Oncology
25%
Gene Mutation
25%
Immune System
25%
Oncogene
25%
Immunotherapy
25%
Tumor Suppressor Protein
25%
Fibroblast Growth Factor Receptor 2
25%
Disease Resistance
25%
Oncogene Addiction
25%
Isocitrate Dehydrogenase 1
25%
Clinical Trial Results
25%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Duct Carcinoma
100%
Disease
50%
Biological Marker
25%
Mortality Rate
25%
Neoplasm
25%
Combination Therapy
25%
Recurrent Disease
25%
Immunotherapy
25%
Tumor Suppressor Protein
25%
Fibroblast Growth Factor Receptor 2
25%
Disease Resistance
25%
Oncogene Addiction
25%
Isocitrate Dehydrogenase 1
25%
Clinical Trial Results
25%